Top 10 Companies in the United States Pharmaceutical Gelatin Market (2026): Market Leaders Shaping U.S. Pharmaceutical Gelatin

Pharmaceutical gelatin plays a pivotal role in the U.S. pharmaceutical sector, underpinning capsule production, tablet coatings, and drug delivery systems. Derived from collagen sourced from bovine hides, pig skin, and bones, it undergoes stringent purification to meet USP and EP standards, guaranteeing safety and efficacy.

United States Pharmaceutical Gelatin Market – View in Detailed Research Report

Market Size

The United States pharmaceutical gelatin market was valued at USD 567.8 million in 2025 and is projected to reach USD 786.4 million by 2034, reflecting a CAGR of 5.6% during the forecast period of 2025 to 2034. This trajectory is driven by escalating demand for gelatin capsules, the rising preference for clean‑label products, and automation‑driven manufacturing efficiencies.

Product Definition

Pharmaceutical gelatin is a vital product in the healthcare and pharmaceutical industries, primarily used in the manufacturing of soft and hard capsules, coatings for tablets, and for various drug delivery applications. It is a purified form of collagen, which is derived from animal sources such as bovine hides, pig skin, and bones. The gelatin undergoes rigorous processing to meet pharmaceutical-grade standards, ensuring it is safe for consumption and effective in drug formulations.

In pharmaceutical formulations, gelatin serves multiple purposes, such as a carrier for active ingredients, a protective barrier, and a means for controlled or sustained release of the drug. Its ability to form a gel-like consistency under specific conditions makes it ideal for encapsulating sensitive pharmaceutical ingredients. Furthermore, gelatin has natural biocompatibility, which ensures it is non-toxic and digestible, making it an essential ingredient in the pharmaceutical sector.

🔟 1. Rousselot

Headquarters: Roussin, France
Key Offering: Pharmaceutical gelatin for capsules and drug delivery systems

Rousselot remains the benchmark for quality, leveraging advanced extraction technologies to deliver gelatin that meets the most stringent USP and EP criteria. Its portfolio spans soft and hard capsules, ensuring consistent performance across a broad range of APIs.

Sustainability & Growth Initiatives:

• Investment in waste‑to‑value processes to minimize animal by‑product waste.
• Collaboration with suppliers to trace and verify animal welfare standards.
• Expansion of halal‑certified gelatin lines to capture niche markets.

9️⃣ 2. Gelita AG

Headquarters: Nuremberg, Germany
Key Offering: Broad range of pharmaceutical-grade gelatin, including plant‑derived alternatives

Gelita AG champions sustainability, integrating circular economy principles into its production. Its advanced purification processes reduce energy consumption while maintaining high purity levels, positioning the company as a leader in eco‑friendly gelatin solutions.

Sustainability & Growth Initiatives:

• Carbon‑neutral manufacturing goal by 2030.
• Strategic partnerships to develop agar‑agar and pectin‑based gelatin.
• Enhanced traceability systems for raw material sourcing.

8️⃣ 3. Catalent Pharma Solutions

Headquarters: Dublin, Ireland
Key Offering: Advanced drug delivery technologies incorporating pharmaceutical gelatin

Catalent’s expertise lies in integrating gelatin into complex delivery platforms, such as controlled‑release tablets and micro‑encapsulation systems, thereby extending therapeutic windows and improving patient adherence.

Sustainability & Growth Initiatives:

• Digital twin technology to optimize gelatin batch performance.
• R&D focus on plant‑based gelatin substitutes.
• Collaborations with global pharma clients to reduce formulation cycle times.

7️⃣ 4. Pfizer Inc.

Headquarters: New York, USA
Key Offering: In‑house gelatin production for a diverse portfolio of vaccines and therapeutics

Pfizer’s internal gelatin capabilities support its extensive vaccine pipeline, ensuring a reliable supply of high‑grade gelatin for capsule and injectable formulations.

Sustainability & Growth Initiatives:

• Integration of renewable energy sources across production sites.
• Partnerships with suppliers to secure animal‑welfare‑certified raw materials.
• Investment in alternative delivery formats to reduce gelatin dependency.

6️⃣ 5. Merck & Co., Inc.

Headquarters: Kenilworth, USA
Key Offering: Pharmaceutical gelatin for capsules and controlled‑release formulations

Merck’s gelatin products underpin a significant portion of its oral drug portfolio, enabling precise dosage control and extended release profiles.

Sustainability & Growth Initiatives:

• Adoption of closed‑loop water recycling systems.
• Strategic sourcing of halal‑certified gelatin for global markets.
• Accelerated R&D into gelatin‑based nanocarriers.

5️⃣ 6. GSK (GlaxoSmithKline)

Headquarters: London, UK
Key Offering: Pharmaceutical gelatin for vaccines and oral therapies

GSK’s gelatin lines support its vaccine production, ensuring compliance with global safety standards while maintaining cost competitiveness.

Sustainability & Growth Initiatives:

• Carbon footprint reduction targets across the supply chain.
• Investment in plant‑derived gelatin for niche therapeutic areas.
• Collaborations with animal‑welfare organizations to certify raw material sources.

4️⃣ 7. Johnson & Johnson

Headquarters: New Brunswick, USA
Key Offering: Pharmaceutical gelatin for a wide range of dosage forms

Johnson & Johnson’s gelatin portfolio is integral to its oral and injectable drug lines, ensuring high purity and consistent performance across global markets.

Sustainability & Growth Initiatives:

• Implementation of zero‑waste manufacturing protocols.
• Development of vegetarian gelatin options for specialty markets.
• Strategic alliances with suppliers to secure sustainable raw materials.

3️⃣ 8. Eli Lilly and Company

Headquarters: Indianapolis, USA
Key Offering: Pharmaceutical gelatin for oncology and diabetes therapeutics

Eli Lilly’s gelatin products are tailored for high‑dose formulations, supporting its expanding portfolio of specialty drugs.

Sustainability & Growth Initiatives:

• Enhanced energy efficiency in gelatin processing units.
• Partnerships to develop plant‑based gelatin for emerging markets.
• Robust traceability systems for raw material sourcing.

2️⃣ 9. AbbVie Inc.

Headquarters: North Chicago, USA
Key Offering: Pharmaceutical gelatin for immunology and virology products

AbbVie’s gelatin lines support its immunology pipeline, delivering high‑purity formulations that meet stringent regulatory requirements.

Sustainability & Growth Initiatives:

• Carbon‑neutral production targets by 2035.
• Investment in halal‑certified gelatin for Middle East markets.
• Digitalization of supply chain to enhance traceability.

1️⃣ 10. Teva Pharmaceutical Industries Ltd.

Headquarters: Israel
Key Offering: Pharmaceutical gelatin for generic and specialty drugs

Teva’s gelatin portfolio underpins its extensive generic drug production, ensuring cost‑effective and compliant dosage forms.

Sustainability & Growth Initiatives:

• Renewable energy integration across manufacturing sites.
• Development of vegetarian gelatin for niche therapeutic areas.
• Strategic sourcing of animal‑welfare‑certified raw materials.

Download FREE Sample Report

Get Full Report

🌍 Outlook: U.S. Pharmaceutical Gelatin Market Trends

The U.S. gelatin market is set to evolve as manufacturers pivot toward cleaner, more sustainable production methods. Regulatory tightening around animal‑derived ingredients and the rising demand for vegetarian and halal alternatives will reshape supply chains. Automation and digital monitoring will continue to drive efficiency gains, while controlled‑release technologies expand the therapeutic reach of gelatin‑based formulations.

📈 Future Trends Shaping the Market

• Accelerated adoption of plant‑derived gelatin to satisfy dietary restrictions.
• Integration of controlled‑release platforms to enhance patient adherence.
• Digital supply‑chain solutions to improve traceability and compliance.
• Strategic collaborations between gelatin producers and pharmaceutical R&D labs.
• Increased focus on circular economy initiatives to reduce waste and carbon footprints.